Cargando…

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma

BACKGROUND: In papillary thyroid carcinoma (PTC), BRAFV600E is a common mutation and is associated with aggressive clinical behaviour. Immunocytochemistry (ICC) and molecular testing are recommended in the Bethesda System for Reporting Thyroid Cytopathology 2017 (TBSRTC) category III, IV and V. AIMS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anand, Nidhi, Agrawal, Tushar, Gupta, Anurag, Shukla, Saumya, Pradhan, Roma, Husain, Nuzhat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489694/ https://www.ncbi.nlm.nih.gov/pubmed/34703086 http://dx.doi.org/10.4103/JOC.JOC_248_20

Ejemplares similares

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

Associations between Bethesda categories and tumor characteristics of conventional papillary thyroid carcinoma
por: Park, Vivian Youngjean, et al.
Publicado: (2018)

Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy*
por: Lourdes Ng, Jennifer, et al.
Publicado: (2023)

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Silver, Jennifer A., et al.
Publicado: (2021)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature
por: Alshaikh, Safa, et al.
Publicado: (2018)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation
por: Poyrazoğlu, Şükran, et al.
Publicado: (2017)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
por: Lin, Yan-Yu, et al.
Publicado: (2023)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer
por: Yoon, Seokho, et al.
Publicado: (2015)

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
por: Zhang, Na, et al.
Publicado: (2017)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV(600E)-Positive Papillary Thyroid Cancer
por: da Silva, Sabrina Daniela, et al.
Publicado: (2022)

The Diagnostic Performance of Thyroid US in Each Category of the Bethesda System for Reporting Thyroid Cytopathology
por: Park, So Yoon, et al.
Publicado: (2016)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF(V600E) Mutation
por: Chirayath, Shiga Rappai, et al.
Publicado: (2019)

Does the Bethesda category predict aggressive features in differentiated thyroid cancer?
por: Lima, Ana Rafaela Lopes Reis, et al.
Publicado: (2019)

Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma
por: Guo, Liang, et al.
Publicado: (2019)

Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy
por: Jensen, Kirk, et al.
Publicado: (2020)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
por: Huang, Shuhui, et al.
Publicado: (2022)

Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography
por: Agyekum, Enock Adjei, et al.
Publicado: (2023)

Diagnostic value of thyroid imaging reporting and data system combined with BRAF(V600E) mutation analysis in Bethesda categories III–V thyroid nodules
por: Wu, Liuxi, et al.
Publicado: (2022)

The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine‐Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment
por: Zha, Xiaojuan, et al.
Publicado: (2022)

The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells()
por: Puli, Oorvashi Roy, et al.
Publicado: (2018)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

Cytomorphologic features distinguishing Bethesda category IV thyroid lesions from parathyroid
por: Sung, Simon, et al.
Publicado: (2017)

BRAF(V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules
por: Wu, Ya, et al.
Publicado: (2019)

BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules
por: Sheng, Danli, et al.
Publicado: (2021)

The Bethesda System thyroid diagnostic categories in the African-American population in conjunction with surgical pathology follow-up
por: Archuletta, Pamela Anne, et al.
Publicado: (2012)

Corrigendum: The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine‐Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment
por: Zha, Xiaojuan, et al.
Publicado: (2022)

Molecular Testing for BRAFV600E and RAS Mutations from Cytoscrapes of Thyroid Fine Needle Aspirates: A Single-Center Pilot Study
por: Gupta, Ojas, et al.
Publicado: (2020)

Non-invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Lowers the Risk of Malignancy in the Bethesda System for Reporting Thyroid Cytopathology Diagnostic Categories
por: Al-Maghrabi, Hatim, et al.
Publicado: (2022)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population
por: Nechifor-Boilă, Adela, et al.
Publicado: (2023)

BRAF(V600E) genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration
por: Lu, Yiran, et al.
Publicado: (2023)

Thyroid Cancer Detection Rate and Associated Risk Factors in Patients with Thyroid Nodules Classified As Bethesda Category III
por: Mileva, Magdalena, et al.
Publicado: (2018)

Hashimoto’s Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2022)

A Study of Thyroid Fine Needle Aspiration of Follicular Adenoma in the “Atypia of Undetermined Significance” Bethesda Category Using Digital Image Analysis
por: Yao, Keluo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfi4u8bj70mn3usl29csrdedqu